In the early 1980s, researchers at Massachusetts General Hospital helped work out the biology behind GLP-1. Now the health system it belongs to is telling some of its own employees it will stop paying for GLP-1s prescribed for weight loss. This is GLP-1 Daily for Friday, October 23. That benefits change at Mass General Brigham comes first. Then British MPs call the NHS plan for Mounjaro too timid, and CBS News sends a corner-store vial of so-called retatrutide to a lab.
Mass General Brigham, in a statement published by On The Pen GLP-1 News:
Beginning January 1, 2027, GLP-1 medications prescribed for weight loss will no longer be covered through the pharmacy benefit of affected Mass General Brigham employee medical plans. Coverage for GLP-1 medications prescribed for diabetes will continue, subject to plan coverage criteria.
On The Pen reported this today, based on a CVS Caremark letter dated October 12 that it obtained. The letter says the member's plan will stop paying for weight-management drugs, and existing prior authorizations expire December 31. It isn't only Wegovy and Zepbound, either. The letter also names Saxenda, Contrave, Qsymia, phentermine and orlistat. What the system offers instead is a Health Reimbursement Arrangement for eligible employees and covered family members, with more help for lower-wage workers, plus a team to explain benefits. It calls this a difficult decision driven by rising drug costs and the long-term affordability of benefits, and says it will keep evaluating. A reimbursement pool beats nothing, and On The Pen concedes that. But it isn't a pharmacy benefit. If the money doesn't cover the full price, the patient pays the rest. And the statement says affected plans, so we don't know how many employees this reaches. About the source: the piece is written from a patient's point of view and openly argues for a reversal. The central fact, though, comes from the system's own statement. On October 14 we covered Walmart adding free diabetes GLP-1s while still refusing to cover them for weight loss. Mass General Brigham is drawing the same line. If your employer's plan changes for 2027, use open enrollment to ask exactly how any reimbursement works and what you'd owe each month. And raise it with your prescriber before January, so you have a plan if coverage ends.
Nick Triggle, health correspondent at BBC News:
The Health Committee said the current plan for 220,000 people to have this jab for free on prescription in 2028 was a "woefully small number" and "unambitious".
That's a cross-party committee of MPs, talking about England. Two hundred twenty thousand people is about six percent of those eligible. The BBC calls that gap a key reason more than a million people are paying privately for injections like Mounjaro and Wegovy. The committee's phrase is a two-tier system, where only the wealthy get good access. Then the money. Because of cost, the NHS is working to a twelve-year rollout, which is now under review. Treating all 2.8 million eligible people at once would cost an estimated fifteen point two billion pounds over five years. The MPs say part of that comes from relying on GPs for prescribing and monitoring, and they want the NHS to learn from private providers' digital platforms. They tie access to the black market too. The committee says scarcity on the NHS pushed people toward unlicensed products online, and it wants a public awareness campaign plus a review of how online advertising is regulated. A waiting list rations care just as surely as a prior auth does. To be clear, this is a recommendation, not a policy change. NHS England says it is looking at ways to speed up the rollout, but for now is prioritizing people with the most severe and complex needs. Wegovy, meanwhile, is available on the NHS only through specialist weight management services.
Adam Yamaguchi, national correspondent for CBS News, in a report from Wednesday:
Instead, Galpin found a compound called phenylacetic acid, which he described as a filler. It's commonly found in fragrances and lip balms.
That vial was sold as retatrutide, Lilly's experimental triple agonist, which is still in clinical trials and not approved. Yamaguchi paid ninety dollars for it at a Brooklyn bodega, and the label said research use only. Jason Galpin, a University of Iowa research scientist, said it didn't look anything like a peptide. A second Iowa lab then counted thirteen colonies of bacteria in it. He also ordered online, once from a clinic started by a nurse practitioner and once from a Florida gym. Both promised a review of some kind, and both shipped without him ever speaking to a health professional. Those two samples matched a basic retatrutide standard Galpin built, which CBS notes is not the same as the drug in Lilly's trials. So the good outcome is roughly the right molecule from an unknown maker, with nobody looking at your history. The bad outcome is a filler and bacteria going under your skin. A Yale physician quoted by CBS says buyers are essentially acting as guinea pigs. Limits: three purchases and lab work arranged by a news outlet, not a survey of the market, and the sellers hadn't responded to CBS. Lilly's statement calls a single test a snapshot, not a guarantee, and says regulators are failing to act. That's the company's view, and Lilly is suing sellers. On October 14 we covered two unverified death reports tied to bootleg retatrutide, and on Wednesday, Belgium's warning about the same market. If a cheap vial of Reta is tempting, have that conversation with your prescriber first, and ask what approved options actually fit you.
A Friday request: if this week's episodes helped you decode a coverage letter or a lab finding, rate GLP-1 Daily in your podcast app. One honest sentence of review helps the next patient find us.
You'll find On The Pen, the BBC and CBS linked in the episode notes. We're taking the weekend and will be back Monday, October 26. GLP-1 Daily is one of the Lantern Podcasts.